Location: Huntsville, AL
CEO: Rob Seitz
CSO: Doug Ross
Board of Directors: Jim Hudson, Roy Nichols, Lonnie McMillian, Rob Seitz, Doug Ross

- Strategically important: Rapidly growing cancer diagnostics company Clarient has the powerful commercial engine that is expected to drive the sale of the proprietary technology/tests developed by AGI.

- Several AGI-developed tests ready for market launch by Clarient at time of the transaction close, including Pulmotype(R) for classifying lung cancer patients.

- AGI uses a proprietary process whereby complex gene expression data is used to target antibody production and generate datasets of protein expression across thousands of tumor tissues.